Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

, BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

11:51
11/23/16
11/23
11:51
11/23/16
11:51

Piper says CAR-T researchers must heed risks highlighted by Juno news

Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

CLLS

Cellectis

$17.94

-0.06 (-0.33%)

CELG

Celgene

$120.97

-3.19 (-2.57%)

BLCM

Bellicum Pharmaceuticals

$20.93

-1.87 (-8.20%)

LBIO

Lion Biotechnologies

$7.25

-0.05 (-0.68%)

NK

NantKwest

$7.45

-0.1 (-1.32%)

  • 23

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CLLS Cellectis
$17.94

-0.06 (-0.33%)

08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
10/27/16
LTCO
10/27/16
NO CHANGE
Target $45
LTCO
Buy
Cellectis recent selloff unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li says the recent pullback in shares of Cellectis is unwarranted. The UCART19 Phase 1 trial is dosing patients on schedule, which is a positive sign for the outcome readout of the trial, Li tells investors in a research note. The analyst recommends buying the shares on the pullback and keeps a Buy rating on the name with a $45 price target.
03/01/16
RHCO
03/01/16
INITIATION
Target $35
RHCO
Buy
Cellectis initiated with a Buy at SunTrust
Target $35.
04/05/16
LTCO
04/05/16
INITIATION
Target $45
LTCO
Buy
Cellectis initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Cellectis with a Buy rating and $45 price target.
CELG Celgene
$120.97

-3.19 (-2.57%)

11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BLCM Bellicum Pharmaceuticals
$20.93

-1.87 (-8.20%)

08/09/16
SBSH
08/09/16
UPGRADE
Target $24
SBSH
Buy
Bellicum Pharmaceuticals upgraded to Buy from Neutral at Citi
Citi analyst Robyn Karnauskas upgraded Bellicum Pharmaceuticals to Buy saying the BPX-501 approval pathway is getting clearer. The analyst has increased confidence in the program and has a $24 price target for the shares.
08/22/16
RHCO
08/22/16
NO CHANGE
RHCO
Bellicum Pharmaceuticals price target raised to $30 from $20 at SunTrust
After meeting with Bellicum's management, SunTrust analyst Peter Lawson is more confident that the company's BPX-501 treatment will be approved. He now sees a 50% chance of approval, up from 30% previously, and thinks the treatment could be approved in the U.S. by the end of this year. He keeps a Buy rating on the stock.
11/01/16
CANT
11/01/16
INITIATION
Target $32
CANT
Buy
Bellicum Pharmaceuticals initiated with a Buy at Cantor
Cantor initiated Bellicum Pharmaceuticals with a Buy and a $32 price target.
LBIO Lion Biotechnologies
$7.25

-0.05 (-0.68%)

06/10/16
06/10/16
NO CHANGE
Target $20

Outperform
FBR adds Corium to Alpha Generator list, removes Lion
FBR Capital analyst Ed White added Corium (CORI) to his firm's Alpha Generator list while removing Lion Biotechnologies (LBIO). Corium is being underestimated by the Street as its management has a well-strategized plan to bring Corplex donepezil and Corplex memantine to market, White contends. He has an Outperform rating on the shares with a $20 price target. The analyst lowered his price target for Lion to $18 following the closing of its private financing. He reiterates an Outperform rating on the shares, however, saying it remains one of his top picks.
07/08/16
ROTH
07/08/16
NO CHANGE
Target $15
ROTH
Buy
Lion T cell therapies not that similar to Juno candidate, says Roth Capital
Roth Capital analyst Joseph Pantginis says yesterday's announcement that the Phase II study of Juno Therapeutic's (JUNO) lead candidate, JCR015, was suspended over the deaths of two patients had ripple effects on the space. However, the analyst points out that while both JCR015 and Lion Biotechnologies' (LBIO) LN-144 are T cell therapies with similar preconditioning regimens, the similarities end there. Lion's T cell therapies have not demonstrated characteristic safety profiles of concern, Pantginis tells investors in a research note. He reiterates a Buy rating and $15 on Lion's shares.
NK NantKwest
$7.45

-0.1 (-1.32%)

12/22/15
ADAM
12/22/15
INITIATION
Target $20
ADAM
Buy
NantKwest initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated NantKwest with a Buy rating and $20 price target on shares.
12/22/15
12/22/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AVANGRID (AGR) initiated with a Neutral at JPMorgan... Accuray (ARAY) initiated with a Sector Perform at RBC Capital... American Express (AXP) initiated with a Market Perform at JMP Securities... BioTime (BTX) initiated with an Outperform at Oppenheimer... Biota Pharmaceuticals (BOTA) initiated with an Outperform at FBR Capital... Box (BOX) initiated with an Outperform at JMP Securities... CNO Financial (CNO) initiated with an Outperform at Raymond James... Capital One (COF) initiated with a Hold at Evercore ISI... Criteo (CRTO) initiated with a Buy at SunTrust... CyberArk (CYBR) initiated with a Hold at Evercore ISI... CyrusOne (CONE) initiated with an Overweight at JPMorgan... Digital Realty (DLR) initiated with a Neutral at JPMorgan... Discover (DFS) initiated with a Hold at Evercore ISI... Etsy (ETSY) initiated with a Sell at Roth Capital... Fenix Parts (FENX) initiated with a Buy at Roth Capital... Fibrocell Science (FCSC) initiated with a Buy at Roth Capital... Franklin Electric (FELE) initiated with a Sell at Ladenburg... Harman (HAR) initiated with a Neutral at Susquehanna... Karyopharm (KPTI) initiated with a Buy at Canaccord... MPLX (MPLX) initiated with a Neutral at Credit Suisse... Marchex (MCHX) initiated with a Buy at Roth Capital... NantKwest (NK) initiated with a Buy at Canaccord... Nexstar (NXST) initiated with an Outperform at Barrington... Orbital ATK (OA) initiated with a Buy at CL King... Perrigo (PRGO) initiated with an Outperform at Northland... QTS Realty Trust (QTS) initiated with an Overweight at JPMorgan... RPC, Inc. (RES) initiated with a Buy at Guggenheim... Rubicon Project (RUBI) initiated with a Buy at SunTrust... Sorrento Therapeutics (SRNE) initiated with an Outperform at FBR Capital... Travelport (TVPT) initiated with a Neutral at SunTrust... TubeMogul (TUBE) initiated with a Buy at SunTrust... Ultragenyx (RARE) initiated with a Buy at Canaccord... Varian Medical (VAR) initiated with a Sector Perform at RBC Capital... Wayfair (W) initiated with a Neutral at SunTrust... Xencor (XNCR) initiated with a Buy at Canaccord.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
NantKwest initiated with a Market Perform at Raymond James

TODAY'S FREE FLY STORIES

AIZ

Assurant

$94.03

-0.05 (-0.05%)

17:10
01/22/18
01/22
17:10
01/22/18
17:10
Syndicate
Breaking Syndicate news story on Assurant »

Assurant files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

FSLR

First Solar

$68.96

-1.07 (-1.53%)

17:08
01/22/18
01/22
17:08
01/22/18
17:08
Technical Analysis
Technical Take: First Solar spikes after tariff decision »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$52.25

-0.25 (-0.48%)

17:05
01/22/18
01/22
17:05
01/22/18
17:05
Earnings
Brown & Brown reports Q4 EPS 47c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EAT

Brinker

$38.39

0.08 (0.21%)

, GS

Goldman Sachs

$261.52

5.4 (2.11%)

17:03
01/22/18
01/22
17:03
01/22/18
17:03
Hot Stocks
Brinker adds James Katzman To Board of Directors »

Brinker (EAT) announces…

EAT

Brinker

$38.39

0.08 (0.21%)

GS

Goldman Sachs

$261.52

5.4 (2.11%)

HSY

Hershey

$109.96

0.59 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

  • 01

    Feb

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EMR

Emerson

$73.26

0.12 (0.16%)

16:29
01/22/18
01/22
16:29
01/22/18
16:29
Initiation
Emerson initiated  »

Emerson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.